Cargando…
P937: CARFILZOMIB, LENALIDOMIDE PLUS DEXAMETHASONE (KRD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE ANALYSIS OF REAL-LIFE EXPERIENCE OF GEMMAC GROUP.
Autores principales: | Garcia-Guiñon, Antonio, Andrea Charry, Paola, Moraima Jimenez, Maria, Sarra Escarre, Jose, Delgado, Izarbe, de la Torre, Laura Segura, Santaliestra Tomas, Marta, Garcia Pintos, Marta, Gonzalez Montes, Yolanda, Magan, Maria Alicia Senin, Motllo, Cristina, Ben Azaiz, Randa, Elena Cabezudo, Maria, Granell Gorrochategui, Miquel, Sancho, Esther, Jose Herranz, Maria, Seres, Yasmina, Gironella, Mercedes, Soler, Juan A, Tutusaus, Jose Maria Marti, Abella Monreal, Eugenia, Fernandez de Larrea, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431517/ http://dx.doi.org/10.1097/01.HS9.0000970652.81324.da |
Ejemplares similares
-
Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
por: Byun, Ja Min, et al.
Publicado: (2020) -
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023) -
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2020) -
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
por: Leypoldt, Lisa B., et al.
Publicado: (2021)